Recurrent hairy cell leukemia variant
Clinical trials for Recurrent hairy cell leukemia variant explained in plain language.
Never miss a new study
Get alerted when new Recurrent hairy cell leukemia variant trials appear
Sign up with your email to follow new studies for Recurrent hairy cell leukemia variant, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA VARIANT
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for rare leukemia: targeted pill tackles relapse
Disease control OngoingThis study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA VARIANT
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC